Sukumar Nagendran

2.9k total citations
15 papers, 514 citations indexed

About

Sukumar Nagendran is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Genetics. According to data from OpenAlex, Sukumar Nagendran has authored 15 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Genetics. Recurrent topics in Sukumar Nagendran's work include Diabetes Treatment and Management (6 papers), Neurogenetic and Muscular Disorders Research (6 papers) and RNA modifications and cancer (5 papers). Sukumar Nagendran is often cited by papers focused on Diabetes Treatment and Management (6 papers), Neurogenetic and Muscular Disorders Research (6 papers) and RNA modifications and cancer (5 papers). Sukumar Nagendran collaborates with scholars based in United States, Germany and India. Sukumar Nagendran's co-authors include Soamnauth Misir, Stacey L. Abby, Jerry R. Mendell, Richard Shell, W. David Arnold, Samiah Al-Zaidy, Courtney Wells, Linda Lowes, Melissa Menier and Lindsay N. Alfano and has published in prestigious journals such as Neurology, Current Medical Research and Opinion and Pediatric Neurology.

In The Last Decade

Sukumar Nagendran

14 papers receiving 498 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sukumar Nagendran United States 8 257 199 198 166 78 15 514
Shivaram Shastri India 14 104 0.4× 45 0.2× 149 0.8× 11 0.1× 30 0.4× 22 571
Saptarshi Bhattacharya India 13 87 0.3× 10 0.1× 134 0.7× 249 1.5× 72 0.9× 92 512
Iolanda Sposato Italy 5 60 0.2× 15 0.1× 77 0.4× 215 1.3× 29 0.4× 5 326
Lijing Jia China 9 85 0.3× 14 0.1× 72 0.4× 145 0.9× 31 0.4× 24 353
Hisakazu Nakajima Japan 11 112 0.4× 13 0.1× 61 0.3× 77 0.5× 86 1.1× 43 389
Christina Pamporaki Germany 16 71 0.3× 37 0.2× 819 4.1× 788 4.7× 37 0.5× 52 1.1k
Ken Ho Australia 6 142 0.6× 12 0.1× 53 0.3× 304 1.8× 82 1.1× 10 492
Halit Diri Türkiye 10 68 0.3× 23 0.1× 42 0.2× 161 1.0× 41 0.5× 30 346
G Grislis United States 9 108 0.4× 36 0.2× 63 0.3× 96 0.6× 15 0.2× 11 409
Joe George India 10 37 0.1× 16 0.1× 95 0.5× 157 0.9× 23 0.3× 19 348

Countries citing papers authored by Sukumar Nagendran

Since Specialization
Citations

This map shows the geographic impact of Sukumar Nagendran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sukumar Nagendran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sukumar Nagendran more than expected).

Fields of papers citing papers by Sukumar Nagendran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sukumar Nagendran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sukumar Nagendran. The network helps show where Sukumar Nagendran may publish in the future.

Co-authorship network of co-authors of Sukumar Nagendran

This figure shows the co-authorship network connecting the top 25 collaborators of Sukumar Nagendran. A scholar is included among the top collaborators of Sukumar Nagendran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sukumar Nagendran. Sukumar Nagendran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Al-Zaidy, Samiah, Stephen J. Kolb, Linda Lowes, et al.. (2019). AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. Journal of Neuromuscular Diseases. 6(3). 307–317. 128 indexed citations
2.
Lowes, Linda, Lindsay N. Alfano, W. David Arnold, et al.. (2019). Impact of Age and Motor Function in a Phase 1/2A Study of Infants With SMA Type 1 Receiving Single-Dose Gene Replacement Therapy. Pediatric Neurology. 98. 39–45. 133 indexed citations
3.
4.
Mendell, Jerry R., Samiah Al-Zaidy, Richard Shell, et al.. (2018). AVXS-101 Phase 1 Gene Replacement Therapy Clinical Trial in SMA Type 1: Continued Event Free Survival and Achievement of Developmental Milestones (S29.001). Neurology. 90(15_supplement). 4 indexed citations
5.
Mendell, Jerry R., Samiah Al-Zaidy, Richard Shell, et al.. (2017). AVXS-101 Phase 1 gene therapy clinical trial in SMA Type 1: Event free survival and achievement of developmental milestones. European Journal of Paediatric Neurology. 21. e13–e14. 2 indexed citations
6.
Shell, Richard, Samiah Al-Zaidy, W. David Arnold, et al.. (2017). AVXS-101 Phase 1 gene therapy clinical trial in SMA Type 1: Interim data demonstrates improvements in supportive care use. European Journal of Paediatric Neurology. 21. e14–e14. 1 indexed citations
7.
Rosenstock, Julio, et al.. (2012). Initial Combination Therapy with Metformin plus Colesevelam in Drug-Naïve Hispanic Patients with Early Type 2 Diabetes. Postgraduate Medicine. 124(4). 7–13. 6 indexed citations
8.
Schwartz, Sherwyn, Yu‐Ling Lai, Jianbo Xu, et al.. (2010). The Effect of Colesevelam Hydrochloride on Insulin Sensitivity and Secretion in Patients With Type 2 Diabetes: A Pilot Study. Metabolic Syndrome and Related Disorders. 8(2). 179–188. 40 indexed citations
9.
Rosenstock, Julio, Vivian Fonseca, W. Timothy Garvey, et al.. (2010). Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes. Endocrine Practice. 16(4). 629–640. 31 indexed citations
10.
Flórez, Hermes, Jiacong Luo, Sumaya Castillo-Florez, et al.. (2010). Impact of Metformin-Induced Gastrointestinal Symptoms on Quality of Life and Adherence in Patients with Type 2 Diabetes. Postgraduate Medicine. 122(2). 112–120. 93 indexed citations
11.
Handelsman, Yehuda, Ronald Goldberg, W. Timothy Garvey, et al.. (2010). Colesevelam Hydrochloride to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study. Endocrine Practice. 16(4). 617–628. 31 indexed citations
12.
Jialal, Ishwarlal, Stacey L. Abby, Soamnauth Misir, & Sukumar Nagendran. (2009). Concomitant Reduction in Low-Density Lipoprotein Cholesterol and Glycated Hemoglobin With Colesevelam Hydrochloride in Patients With Type 2 Diabetes: A Pooled Analysis. Metabolic Syndrome and Related Disorders. 7(3). 255–258. 28 indexed citations
13.
Jones, Michael R., Sunder Mudaliar, AG Unnikrishnan, et al.. (2009). Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Current Medical Research and Opinion. 25(9). 2239–2249. 13 indexed citations
14.
Jones, Michael R., Vivian Fonseca, Stacey L. Abby, Allison B. Goldfine, & Sukumar Nagendran. (2008). 305: Response to Colesevelam HCl in Patients with Type 2 Diabetes. Journal of clinical lipidology. 2(3). 229–229. 2 indexed citations
15.
Jones, Michael, Julio Rosenstock, Stacey L. Abby, & Sukumar Nagendran. (2008). 306: Colesevelam HCl in Type 2 Diabetes Reduces A1C and LDL-C Consistently Across Age, Gender, and Race. Journal of clinical lipidology. 2(3). 229–230. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shivaram Shastri Breakdown of academic impact, for papers by Saptarshi Bhattacharya Breakdown of academic impact, for papers by Iolanda Sposato Breakdown of academic impact, for papers by Lijing Jia Breakdown of academic impact, for papers by Hisakazu Nakajima Breakdown of academic impact, for papers by Christina Pamporaki Breakdown of academic impact, for papers by Ken Ho Breakdown of academic impact, for papers by Halit Diri Breakdown of academic impact, for papers by G Grislis Breakdown of academic impact, for papers by Joe George
Rankless by CCL
2026